| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 7. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | oxycodone hydrochloride (Onexila XL®) |
| Formulation | 10 mg, 20 mg, 40 mg and 80 mg prolonged-release tablet |
| Reference number | 3464 |
| Indication | In adults, and adolescents aged 12 years and older for the treatment of severe pain, which can be adequately managed only with opioid analgesics |
| Company | Aspire Pharma Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 15/03/2017 |